Founded in 1997, EUFETS AG is a specialist in services for innovative therapeutic approaches. Since 2001, EUFETS AG has been part of Fresenius Biotech GmbH.

Based on extensive expertise in molecular biology, virology and cell biology as well as an understanding of the regulatory prerequisites, the major goal of EUFETS AG is the support of clients developing innovative gene and cell therapies through development, testing and manufacturing services.
We offer our customers a complete service spectrum from gene through clinical trial medication to in-market supply, providing every step from gene expression to cGMP manufacturing, including full project management support.
Since 2003, EUFETS AG has been certified as a GLP laboratory, providing a comprehensive package of special analytical in vitro assays facilitating our clients’ preclinical programs.
Our services are fully integrated and supervised by our Quality Assurance department to ensure that each individual development step will contribute towards obtaining the most efficient and compliant manufacturing process.

EUFETS AG employs more than 30 experienced scientists, technicians and project managers.
The company has more than 600 squaremeters of R&D, QC and GLP laboratories and a 500 squaremeters state-of-the-art GMP facility. All laboratories are BSL 2 & 3** classified.

EUFETS AG so far has produced more than1000 products for cellular therapies and has been involved in numerous clinical trials for gene therapy throughout Europe.